Flecainide challenge test for the diagnosis of Brugada syndrome
نویسندگان
چکیده
منابع مشابه
Evaluation of baseline ECG in patients undergoing Oral Flecainide Challenge test for suspected Brugada Syndrome: An analysis of lead II
BACKGROUND AND OBJECTIVES We analyzed Lead II in patients undergoing an Oral Flecainide Challenge test (FCT), to identify any pointers that could predict a positive FCT and thereby help in recognition of latent BS. METHODS The following parameters in lead II were retrospectively analyzed from the pre-test ECG in 62 patients undergoing FCT for suspected BS: The presence or absence of S waves, ...
متن کاملThe elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge.
BACKGROUND Defects of the SCN5A gene encoding the cardiac sodium channel are associated with both the LQT3 subtype of long-QT syndrome and Brugada syndrome (BS). The typical manifestations of long-QT syndrome (QT interval prolongation) and BS (ST segment elevation in leads V1 through V3) may coexist in the same patients, which raises questions about the actual differences between LQT3 and BS. I...
متن کاملDelayed diagnosis of Brugada syndrome in a patient with aborted sudden cardiac death and initial negative flecainide challenge
A negative flecainide challenge does not rule out Brugada syndrome even in the presence of nonfatal cardiac arrest as the first manifestation of the disease. This should prompt clinicians to ensure long-term ECG follow-up and consider repeating a drug test with another sodium channel blocker.
متن کاملIntravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome.
OBJECTIVES The purpose of this study was to compare the effect of intravenous flecainide and ajmaline with respect to their ability to induce or accentuate the typical ECG pattern of Brugada syndrome. BACKGROUND Brugada syndrome is associated with a high incidence of sudden cardiac death. The typical ECG pattern of ST-segment elevation in the right precordial leads often is concealed, but it ...
متن کاملDiagnosis of Brugada Syndrome
Implantable cardioverter defibrillator (ICD) is considered to be the main therapy for prevention of sudden cardiac death in patients with Brugada syndrome (BrS). However, there have been several reports suggesting a higher prevalence of complications, such as inappropriate shocks, lead failure, and device infection compared with the incidence of lethal ventricular arrhythmia. BrS is mainly diag...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Postgraduate Medical Journal
سال: 2004
ISSN: 0032-5473
DOI: 10.1136/pgmj.2003.017160